1. Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology
   Lili Yan et al, 2022, Frontiers in Molecular Biosciences CrossRef
2. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
   Christopher Schorr et al, 2022, Frontiers in Immunology CrossRef
3. Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia
   Aysha S. Ansari et al, 2024, Acta Biomaterialia CrossRef
4. PROTACs: The Future of Leukemia Therapeutics
   Zubair Anwar et al, 2022, Frontiers in Cell and Developmental Biology CrossRef
5. Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients
   Ali Hazazi et al, 2022, Biosciences Biotechnology Research Asia CrossRef
6. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
   Hirofumi Tsuzuki et al, 2022, Oncotarget CrossRef
7. PRICKLE1, a Wnt/PCP signaling component, is overexpressed and associated with inferior prognosis in acute myeloid leukemia
   Duanfeng Jiang et al, 2021, Journal of Translational Medicine CrossRef
8. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met
   Tahereh Damghani et al, 2021, Scientific Reports CrossRef
9. G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models
   Hae Dong Kim et al, 2021, Frontiers in Pharmacology CrossRef
10. Simultaneous Detection of a Cluster of Differentiation Markers on Leukemia-Derived Exosomes by Multiplex Immuno-Polymerase Chain Reaction via Capillary Electrophoresis Analysis
    Netrapal Singh et al, 2020, Analytical Chemistry CrossRef